Assembly Biosciences (FRA:V7B) Cyclically Adjusted Revenue per Share: €9.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V7B Assembly Biosciences Inc FRA:V7B
37 GF Score
Price €21.85
GF Value €17.56
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Cyclically Adjusted Revenue per Share?

Assembly Biosciences FRA:V7B -2.67% 37 Cyclically Adjusted Revenue per Share is €9.35 as of Mar. 2026. GuruFocus rates FRA:V7B with a GF Score™ of 37/100 and a GF Value™ of €17.56 (Modestly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Assembly Biosciences's adjusted revenue per share for the three months ended in Mar. 2026 was €0.420. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Assembly Biosciences's average Cyclically Adjusted Revenue Growth Rate was -5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Assembly Biosciences was 3.40% per year. The lowest was 3.40% per year. And the median was 3.40% per year.

As of today (2026-07-26), Assembly Biosciences's current stock price is €21.85. Assembly Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €9.35. Assembly Biosciences's Cyclically Adjusted PS Ratio of today is 2.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Assembly Biosciences was 45.56. The lowest was 0.73. And the median was 3.07.


Assembly Biosciences  (FRA:V7B) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Assembly Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.85/9.35
=2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Assembly Biosciences was 45.56. The lowest was 0.73. And the median was 3.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Assembly Biosciences Cyclically Adjusted Revenue per Share Related Terms


Assembly Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Cyclically Adjusted Revenue per Share Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 11.57 10.95 9.41

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.87 10.11 9.51 9.41 9.35

FRA:V7B vs CTNM, PRTA, RGNX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted PS Ratio falls into.


FRA:V7B
37GF Score
Assembly Biosciences Inc FRA:V7B
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Assembly Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.42/330.2130*330.2130
=0.420

Current CPI (Mar. 2026) = 330.2130.

Assembly Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.445 243.801 0.603
201706 1.453 244.955 1.959
201709 1.543 246.819 2.064
201712 1.768 246.524 2.368
201803 1.715 249.554 2.269
201806 1.609 251.989 2.108
201809 1.772 252.439 2.318
201812 1.545 251.233 2.031
201903 1.607 254.202 2.088
201906 1.271 256.143 1.639
201909 1.780 256.759 2.289
201912 1.855 256.974 2.384
202003 1.263 258.115 1.616
202006 11.250 257.797 14.410
202009 9.931 260.280 12.599
202012 0.286 260.474 0.363
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 1.400 274.310 1.685
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 1.234 306.746 1.328
202403 0.971 312.332 1.027
202406 1.405 314.175 1.477
202409 0.971 315.301 1.017
202412 1.075 315.605 1.125
202503 1.161 319.799 1.199
202506 1.090 322.561 1.116
202509 0.725 324.800 0.737
202512 2.288 324.054 2.331
202603 0.420 330.213 0.420

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €9.35 mean?
Assembly Biosciences (FRA:V7B) has a Cyclically Adjusted Revenue per Share of €9.35 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Cyclically Adjusted Revenue per Share too high?
Assembly Biosciences' current Cyclically Adjusted Revenue per Share is €9.35. Overall, Assembly Biosciences has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Cyclically Adjusted Revenue per Share compare to CTNM and PRTA?
Assembly Biosciences' Cyclically Adjusted Revenue per Share of €9.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Cyclically Adjusted Revenue per Share is €9.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Assembly Biosciences (FRA:V7B) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.56, compared to a current price of €21.85 — trading 24.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €9.35. Assembly Biosciences' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Assembly Biosciences (FRA:V7B), the current Cyclically Adjusted Revenue per Share is €9.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Assembly Biosciences (FRA:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €21.85 is trading 24.4% above its estimated GF Value™ of €17.56. GuruFocus considers Assembly Biosciences to be Modestly Overvalued.

Key valuation signals for FRA:V7B:

  • Cyclically Adjusted Revenue per Share: €9.35
  • GF Value™: €17.56 vs. price of €21.85 (24.4% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the FRA:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Assembly Biosciences Business Description

Other Exchanges ASMB:USAV7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
37GF Score

Get the complete analysis for FRA:V7B

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.85
Price
€17.56
GF Value